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GABAPrecise regulation of the intracellular concentration of chloride [Cl−]i is necessary for proper cell volume
regulation, transepithelial transport, and GABA neurotransmission. The Na–K–2Cl (NKCCs) and K–Cl (KCCs)
cotransporters, related SLC12A transporters mediating cellular chloride inﬂux and efﬂux, respectively, are key
determinants of [Cl−]i in numerous cell types, including red blood cells, epithelial cells, and neurons. A common
“chloride/volume-sensitive kinase”, or related system of kinases, has long been hypothesized to mediate the
reciprocal but coordinated phosphoregulation of the NKCCs and the KCCs, but the identity of these kinase(s) has
remained unknown. Recent evidence suggests that the WNK (with no lysine = K) serine–threonine kinases
directlyor indirectly via thedownstreamSte20-typekinases SPAK/OSR1, are critical components of this signaling
pathway. Hypertonic stress (cell shrinkage), and possibly decreased [Cl−]i, triggers the phosphorylation and
activation of speciﬁcWNKs, promoting NKCC activation and KCC inhibition via net transporter phosphorylation.
Silencing WNK kinase activity can promote NKCC inhibition and KCC activation via net transporter
dephosphorylation, revealing a dynamic ability of the WNKs to modulate [Cl−]. This pathway is essential for
the defenseof cell volumeduring osmotic perturbation, coordination of epithelial transport, and gatingof sensory
information in the peripheral system. Commiserate with their importance in serving these critical roles in
humans, mutations in WNKs underlie two different Mendelian diseases, pseudohypoaldosteronism type II (an
inherited form of salt-sensitive hypertension), and hereditary sensory and autonomic neuropathy type 2.WNKs
also regulate ion transport in lower multicellular organisms, including Caenorhabditis elegans, suggesting that
their functions are evolutionarily-conserved. An increased understanding of how the WNKs regulate the Na–K–
2Cl and K–Cl cotransporters may provide novel opportunities for the selective modulation of these transporters,
with ramiﬁcations for common human diseases like hypertension, sickle cell disease, neuropathic pain, and
epilepsy.gery, Massachusetts General
-Bigelow Building Room #502,
K.T. Kahle).
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Any mechanism that makes a homeostatic adjustment in
response to a physiological perturbation requires sensors that
detect the abnormality in the system and transducers that
propagate the signal, once detected, to the appropriate effectors,
which elicit the corrective response. Such mechanisms are often
complex, with multiple components at each step, many times
operating in parallel. Molecular genetics can deﬁne critical genes in
such complex regulatory pathways in an unbiased way, paving the
way for novel and unanticipated physiological insights. In 2001, a
positional cloning effort performed by Lifton and colleagues in the
quest for the genes underlying themonogenic form of hypertension
with hyperkalemia named pseudohypoaldosteronism type II
(PHAII; Online Mendelian Inheritance in Man (OMIM) no.
145260) resulted in the identiﬁcation of the human genes encodingthe human WNK kinases (1). Intronic deletions in WNK1 were
found in affected patients of two different large PHAII families
previously linked to the chromosome 12 PHAII locus, and were
associated with a greater than 5-fold increase inWNK1 expression,
suggesting that mutations were gain-of-function. In other families
previously linked to the chromosome 17 PHAII locus, four different
charge-changing missense mutations inWNK4were found, three of
which clustered in a highly-conserved stretch of ten amino acids
located distal to the molecule's ﬁrst coiled-coil domain, while the
fourth mutation was located just beyond the second coiled-coil
domain. These genetic ﬁndings revealed a completely novel
pathway important for the regulation of blood pressure and
electrolyte homeostasis in humans, and spawned investigation
into the mechanism by which the WNKs achieve these crucial
functions (1).
Physiological experiments in Xenopus laevis oocytes, mammalian
cells, and mouse models have subsequently shown that WNK1 and
WNK4 are multifunctional molecular switches with diverse actions
on multiple targets of ion transport in the aldosterone-sensitive
distal nephron, including the thiazide-sensitive Na–Cl cotransporter
NCC [2]. Through their diverse but coordinated actions on
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potassium ﬂux, achieved via multiple catalytic states of its kinase
domain that is regulated by upstream stimuli like serum potassium,
angiotensin II, and aldosterone, the WNK1 and WNK4 kinases
regulate renal salt and potassium homeostasis. These studies opened
new avenues into the understanding of kidney physiology, including
the long-standing problem of the “aldosterone paradox”, which
refers to the question of how aldosterone can be at the same time a
sodium-retaining and potassium-secreting hormone [3].
TheWNKkinases (withno lysine=K),ﬁrst discovered and cloned in
rat, comprise a subfamily of protein serine–threonine kinases that lack a
well-conserved lysine in β strand 3 of kinase subdomain II that is crucial
for ATP-binding and the catalysis of phosphoryl transfer [4]. The
catalytic activation loop inWNK kinases is remodeled such that a lysine
(Lys-233 inWNK1) in β strand 2 serves this role [5]. Distant relatives of
the WNK kinases are the mammalian Ste20-type serine–threonine
kinases, named for their founding member that is a mitogen-activated
protein kinase kinase kinase kinase (MAP4K) in the yeast MAPK
signaling pathway [6]. WNK1 was the ﬁrst mammalian member of
this kinase family to be cloned [4]; in humans, rodents, and other
mammals, a total of four WNK kinases exist [1,7]. In humans, WNK1 is
encoded on chromosome 12, WNK2 on chromosome 9,WNK3 on the X
chromosome, andWNK4on chromosome17 [1,7].WNKkinases appear
to be expressed in most, if not all, multicellular organisms; for example,
a single WNK ortholog exists in Drosophila melanogaster and Caenor-
habditis elegans, while at least nine orthologs exist in Arabidopsis
thaliana [7]. Although WNK kinases have not been found in the yeast
Saccharomyces cerevisiae, the ﬁrst reported WNK sequence was
identiﬁed in the fungus Phycomyces, leaving unanswered the question
as to whether WNK kinases exist in unicellular organisms.
HumanWNK kinases exhibit high sequence similarity within their
amino-terminal kinase domains, two coiled-coil domains, and an
auto-inhibitory domain [1,4,7]. WNK kinases probably exist as
oligomers (possibly homo-tetramers); however, the kinase activity
does not require oligomerization [8]. Oligomerization may help to
increase the scaffolding function of the large carboxy-terminal
domain that contains multiple sites for protein–protein interactions
(e.g., several PXXPmotifs that can interact with SH3 domains on other
proteins). While stable WNK–WNK heteroligomers have not been
detected, speciﬁc members of theWNK kinase family (e.g., WNK1 and
WNK4) have been shown to phosphorylate each other [8,9].
At the time of their identiﬁcation as human disease genes, little
was known about WNK kinase function other than that the autopho-
sphorylation of the rat homologue of the human WNK1 gene was
increased in response to hypertonic stimuli like NaCl, mannitol, or
sucrose [4]. This ﬁnding was prescient, as several years later, the ﬁrst
report surfaced that demonstrated WNKs were not only important
regulators of the renal-speciﬁc NCC, but also the genetically-related
Na–K–2Cl and K–Cl cotransporters [10–12], which were known to be
reciprocally activated and inhibited, respectively, by serine–threonine
phosphorylation triggered by extracellular hypertonicity [13–17].
Exploration into non-renal targets of the WNK kinases was in part
spurned by the ﬁnding that theywere shown to be discretely localized
to epithelia such as bile ducts, pancreatic ducts, and the choroid
plexus, as well as in non-epithelial cells like neurons [10,18].
A critical link occurred when Delpire and colleagues found that the
WNK kinases physically interacted with the Ste20-type kinases SPAK
and OSR1, which were known to bind, phosphorylate, and stimulate
the activity of NKCC1 [19–21]. The ﬁrst experiments to show that a
WNK kinase functionally regulated a Na–K–2Cl [10] or K–Cl
cotransporter [11,22] were performed in oocytes, paving the way
for additional studies that deﬁned the mechanism of this regulation in
oocytes and other model systems [12].
Subsequent work has established the current paradigm that
different WNK kinase osmosensors, sensitive to changes in extracel-
lular tonicity and possibly intracellular [Cl−]i, via their interactionwith the associated downstream SPAK and OSR1 transducer kinases,
reciprocally but coordinately regulate the effector Na–K–2Cl and K–Cl
cotransporters to defend cell volume, control epithelial transport, and
potentially regulate [Cl−]i in central and peripheral neurons to help
determine the polarity of GABAergic neurotransmission [23,24].
Commiserate with their importance in serving these critical roles in
humans, mutations in WNKs underlie two different Mendelian
diseases, PHAII [1] and hereditary sensory and autonomic neuropathy
type 2 (HSAN2; 25). Moreover, the WNK pathway is also important in
regulating ion transport in lower multicellular organisms, including
worms [26], and also plants [27], suggesting that the WNKs are
evolutionarily-selected to regulate osmotic homeostasis.
This review will attempt to synthesize the current molecular
genetic, biochemical, and physiological data regarding the WNK
kinases and their phosphoregulation of the Na–K–2Cl and K–Cl
cotransporters, with a focus on their roles in cell volume regulation.
We will also speculate on potential roles of the WNKs on GABAergic
signaling in the brain and peripheral nervous system. Other recent
papers have comprehensively covered the roles of the WNKs in
regulating renal transepithelial transport and the pathogenesis of
hypertension [e.g., 28,29], along with the roles of the WNK-associated
Ste20-type kinases SPAK and OSR1 [e.g., 24].
2. The Na–K–2Cl and K–Cl cotransporters: coordinated roles in cell
volume regulation and GABAergic signaling
The Na–K–2Cl and K–Cl cotransporters are SLC12A cation/chloride
cotransporters (CCCs) that mediate epithelial transport, maintain
cellular volume, and regulate GABAergic neurotransmission [30]. The
Na–(K)–2Cl cotransporters execute the coupled movement of sodium
and chloride, with or without potassium, into cells and include the
bumetanide-sensitive NKCC1 (ubiquitously expressed), the furose-
mide-sensitive NKCC2 (expressed in the kidney's thick ascending
limb), and the thiazide-sensitive NCC (expressed in the kidney's distal
convoluted and connecting tubules) [17,30]. Mutations in NKCC2 and
NCC, respectively, cause Bartter's syndrome type I [OMIM no. 601678]
and Gitelman's syndrome (OMIM no. 263800), autosomal recessive
diseases characterized by low blood pressure due to renal salt
wasting, and hypokalemic alkalosis [31,32]. The K–Cl cotransporters
(KCC1, KCC2, KCC3, and KCC4) transport chloride coupled with
potassium, mediating net chloride transport out of cells [16]. KCC1 is
ubiquitously expressed [33], while KCC2 is expressed exclusively in
neurons [34]. KCC3 is highly expressed in neurons and renal epithelia
[35], and loss-of-function mutations in KCC3 cause a severe inherited
peripheral neuropathy associated with agenesis of the corpus
callosum termed Andermann's syndrome [OMIM no. 218000; 36].
KCC4 is highly expressed in renal and inner ear epithelia, and in
neurons and glia in various regions of the CNS [37].
2.1. Roles in cell volume regulation
The volume of mammalian cells (which lack cells walls) is
incessantly challenged by changes in extracellular tonicity, the
transport of osmotically-active substances across the cell membrane,
and the formation or disappearance of intracellular osmoles [38].
This is a particular problem for neurons, which experience large
ﬂuxes of ions during action potential generation; epithelial cells,
which are responsible for transporting solute and water across their
membranes to achieve the homeostasis of bodily ﬂuids like blood,
cerebrospinal ﬂuid, pancreatic juice, bile, and seminal ﬂuid; and red
blood cells, which experience changes in extracellular osmolality,
especially during their transit through blood vessels traversing the
hypertonic interstitium of the renal medulla. Because alterations of
cell volume can jeopardize the structural integrity and intracellular
milieu of cells, the continued operation of cell volume regulatory
mechanisms is required tomaintain proper cell function and survival
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sensors, transducers, and effectors, often operating in parallel
pathways [39].
Cells are able to rapidly respond to perturbations in cell volume by
dynamicallyalteringtheir levelof intracellularsolute(Fig.1). Inhypotonic
extracellular conditions, abrupt cell swelling results in a homeostatic
counter-response termed regulatory volume decrease (RVD), which
triggers a corrective release of K+ and Cl− via K–Cl cotransport through
KCCs, and/or separate K+ and Cl− channels [38–40]. Cell shrinkage
triggers regulatory volume increase (RVI), which results in ion accumu-
lation via Na–K–2Cl cotransport, Na+/H+ exchange, or Na+ channels
[38–40]. To prevent futile cycling and needless energy expenditure, the
NKCCs and the KCCs are coordinately and reciprocally regulated during
these cell volumeregulatorymechanisms;RVDresults in theactivationof
KCCs and inhibitionof theNKCCs,whileRVI results in the inhibitionof the
KCCsandactivationoftheNKCCs[41].Thisregulationislargelyachievedby
serine/threoninephosphorylationanddephosphorylation[16,17,42–44].
Evidencefromkineticstudies,manydoneinredbloodcells,ﬁrstsuggested
thatacommonvolume/chloride-sensitivekinasemediatesthephosphor-
egulation of both pathways [13,41,45–48]. In this model, cell shrinkage
and/or decreases in intracellular chloride activate the kinase(s),which in
turn phosphorylates theNKCCs andKCCs, promoting their activation and
inactivation, respectively; cell swelling and/or increases in intracellular
chloride inhibitskinaseactivity,promotingnetdephosphorylationofboth
cotransporters, thereby resulting in the inhibition of NKCC and activation
of KCC [13]. Pathologic alterations in CCC activity have been shown to
contribute to thealtered cell volume regulation in red blood cells in sickleFig. 1. Reciprocal phosphoregulation of the Na–K–2Cl and K–Cl cotransporters triggered
by changes in extracellular tonicity or intracellular chloride concentration [Cl−]i. In
many cell types, including epithelial cells and red blood cells, hypertonic conditions and
cell shrinkage stimulate cotransporter phosphorylation (P), resulting in NKCC1
activation and K–Cl cotransporter inhibition (shown), contributing to regulatory
volume increase. Conversely, hypotonicity and cell swelling promote cotransporter
dephosphorylation, resulting in NKCC1 inhibition and K–Cl cotransporter inhibition
(not shown), contributing to regulatory volume decrease. In GABAergic neurons, the
balance between NKCC1 and K–Cl cotransporter activities sets [Cl−]i, which along with
the membrane potential, determines the directionality of the cellular ﬂux of Cl− and
the neuronal response to GABA (whose receptor functions as a Cl− channel). With high
NKCC1 activity and low KCC2 activity, GABA signaling is excitatory; the converse is true
when NKCC1 activity is low, and KCC2 activity is high. A common Cl−/volume-
sensitive kinase has been proposed to reciprocally and coordinately phosphoregulate
the NKCCs and the K–Cl cotransporters.cell disease [49–51] and in neurons in neurodegenerative disorders [52].
Despite this important homeostatic mechanism, the identity of the
“chloride/volume-sensitive” kinase of the Na–K–2Cl and K–Cl cotran-
sporters has been amatter of speculation, until recently.
2.2. Roles in GABAergic neurotransmission
NKCC1 and the KCCs also play an important role in establishing the
level of intracellular Cl− [Cl−]i in neurons, which determines the
polarity (excitatory versus inhibitory) of the response to the
neurotransmitter γ-aminobutyric acid (GABA), because the GABAA
receptor is coupled to a chloride channel [53,54] (Fig. 1). During early
development,NKCC1activity ishighandKCC2activity is low,resulting
in a high [Cl−]I and excitatory GABAergic signaling [55–58]. The
developmental switch from excitatory to inhibitory GABA signaling
occurs shortly after birth in the rat, but in other species exhibits
heterogeneity in the timing of this switch [56,57,59]. In the adult
mammalian CNS, highKCC2 activity and lowNKCC1 result in very low
[Cl−]i, and consequently, inhibitory GABAergic signaling in most
neuronal populations [57]. Interestingly, certain anatomic popula-
tions of neurons in the adult showcycled variation in their response to
GABA from excitatory to inhibitory [60] due to the dynamic
modulation of [Cl−]i secondary to variations in CCC activity [61].
The mechanisms underlying the switches in GABAergic signaling are
not all simply due to alterations in CCC expression, suggesting that
dynamic phosphorylation mechanisms might also play a role in this
switch — both in development, and in circadian rhythms [54].
Pathologic alterations in NKCC1 and KCC activity have been shown
to result in the alterations in [Cl−]i homeostasis and aberrant
GABAergic neurotransmission that contributes to the hypo-excitabil-
ity or hyper-excitability of neurons in neonatal seizures [54,62],
temporal lobe epilepsy [63,64], and neuropathic pain [65,66].
However, the kinases that mediate these dynamic ﬂuctuations in
NKCC1 andKCC activity in the central andperipheral nervous systems
are unknown.
3. The WNK kinase “osmosensor”
Hyperosmotic stress and cell shrinkage activates WNK1 by
stimulating its phosphorylation at critical regulatory residues.
Extracellular hyperosmotic conditions (e.g., sorbitol, NaCl, and KCl),
but not other stresses (e.g., H2O2, anisomycin, phosphatase inhibitors,
growth factors, cytokines, phorbol esters) rapidly (within 0.5 min)
activate endogenous WNK1 in multiple mammalian cell types by
increasing its phosphorylation at Ser382 within the T-loop of its
kinase domain [4,8,67]. Mutation of Ser382 to Ala prevents WNK1
activation by hypertonicity, whereasmutation of Ser382 to Glu, which
mimics phosphorylation, increases WNK1 activity and prevents
further activation by hypertonic conditions [67]. Ser382 and the
residues surrounding it are identical in all WNK isoforms, and
conserved in the D. melanogaster and C. elegans WNK1 homologues
[67]. At present, is unclear how WNK1 is activated by the shrinkage-
induced phosphorylation at Ser382, though evidence at present favors
a trans autophosphorylation reaction, suggesting that WNK1 is itself
an “osmosensor.”When expressed in E. coli, wild-type but not kinase-
inactive WNK1 is still phosphorylated at Ser382, while in mammalian
cells, a recombinant kinase-inactive WNK1 mutant can still be
normally phosphorylated at Ser382 in response to sorbitol, suggesting
that endogenous WNK1 is able to transphosphorylate the kinase-
inactive WNK1 mutant [67]. Additional mechanisms that could
explain these data include phosphorylation of WNK1 by another
upstream kinase that is itself the osmosensor, or the inhibition of a
protein phosphatase. Further studies are required to investigate these
possibilities.
Hyperosmotic stress also activates SPAK and OSR1, interacting
downstream kinases of the WNKs (see below) by stimulating their
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(Thr-233 and Ser-373 of SPAK) [67]. Critically, these sites have been
shown previously to be phosphorylated by WNK1 in vitro [68,69], and
genetic suppression of WNK1 decreases basal and sorbitol-induced
activationofSPAK/OSR1andphosphorylation[67,70].Thesedatasuggest
that SPAK and OSR1 are likely not themselves osmosensors. Sorbitol
induces a dramatic re-localization of WNK1 from the cytosol to
intracellularvesicles thatco-localizewithclathrinandAP-1,andpartially
with TGN46, suggesting that a considerable pool ofWNK1 is localized to
TGN/recycling endosomes after hyperosmotic stress [67]. This effect of
hypertonicityonWNK1ismediatedbyitsc-terminalnon-catalyticregion
[67]. Thisﬁnding is compelling, given the fact that theover-expressionof
several different WNK kinases affects the trafﬁcking of multiple ion
channels and cotransporters between intracellular vesicles and the
plasma membrane. For example, catalytically-inactive WNK1 or -4
decreases the membrane expression of the renal outer medullary
potassium channel (ROMK) through a clathrin-dependent endocytosis
[2]. It isalso interestingthatSPAKhasbeenshownto translocate fromthe
cytoplasm to the cytoskeleton in response to hypertonicity [71].
Together, these data highlight the effects that hypertonicity and
cell shrinkage have on WNK1 phosphorylation, activity, and cellular
localization, as well the WNKs' interaction with its downstream
kinase partners SPAK and OSR1. At present, it is unclear whether
WNK2, -3, and -4 isoforms are regulated in a manner similar to
WNK1; however, the fact that Ser382 is conserved among all WNK
isoforms in different species suggests that a common mechanism
may exist among the differentWNKs. Future experimentswill also be
needed to explore whether theWNKs' regulation of ion channels and
other cotransporters is mediated in part through its translocation of
to the TGN/recycling endosomes upon exposure to hyperosmotic
stress or changes in intracellular ion content.
4. WNK kinase regulation of Na–K–2Cl cotransport via the
transducer SPAK/OSR1 kinases
Themammalian Ste(sterile)20-type kinases, named after their yeast
homolog originally discovered in a genetic analysis of S. cerevisiae
mating, include the Ste20/Sps1-related proline/alanine-rich kinase
(SPAK) and the oxidative-stress responsive kinase 1 (OSR1), genes
orthologous to D. melanogaster Fray and the C. elegans GCK-3. SPAK and
OSR1 are highly expressed in neurons and chloride-transporting
epithelia, including the distal nephron [72,73]. Low intracellular
chloride or extracellular hypertonicity activate SPAK and OSR1 in a
manner that is dependent onWNK kinases, as it is abrogated by genetic
ablation of WNK1 or WNK4 kinase activity [67,68,73,74]. SPAK and
OSR1 are key substrates downstream of theWNK kinases in a signaling
cascade that regulates the activity of the NKCCs. This model has been
shaped by biochemical data showing thatWNKs physically interact and
phosphorylate SPAK/OSR1 [19,20,68,69,75], and functional data show-
ing that an interaction between speciﬁc WNKs, SPAK/OSR1, and NKCCs
is required for cotransporter activation [12,76,77].
Delpire and colleagues ﬁrst demonstrated that SPAK and OSR1
physically interact with NKCC1 and KCCs via a speciﬁc conserved
carboxy-terminal (CCT) domain [19,20]. This motif of OSR1 and SPAK
recognizes a Arg-Phe-Xaa-Val (RFXV) domain harbored in the
cytoplasmic amino-terminal tails of NKCCs and the KCCs [19,20,69]
The SPAK/OSR1 CCT domain also binds RFXV domains embedded
within the carboxyl termini of WNK1 and WNK4 [12,19,20,68,69,74].
The physical binding of SPAK to WNK1/4 and NKCC1 is necessary for
cotransporter activity under both baseline and hyperosmotic condi-
tions [68,69,74,76]. Villa et al. have delved into the structural
mechanism by which the CCT domain of SPAK/OSR1 interacts with
the RFXV motif of the WNKs and NKCC1 by solving the crystal
structure of the CCT domain of OSR1 in complex with a peptide of
WNK4 containing the RFXV motif at a resolution of 1.95 Å [78]. These
studies revealed that OSR1's CCT domain forms a novel protein foldthat bindsWNK4's RFXVmotif through a surface-exposed groove via a
complex web of interactions that included a Thr residue (Thr 1008)
positioned just after its RFXVmotif. Delpire and colleagues had shown
previously that RFXVmotifs inWNK1/4 (and other known or putative
SPAK/OSR1-binding proteins) are preceded by such serine or
threonine residues [79]. The structure of the WNK4–OSR1 complex
suggests that phosphorylation of threonine 1008 in WNK4 would
result in a steric clash with the backbone of the CCT domain,
potentially preventing the binding of WNK4 to OSR1's CCT domain
[78]. Interestingly, a biotinylated WNK4 RFXV-pT peptide, in which a
threonine residue equivalent to threonine 1008 in WNK4 is
phosphorylated, failed to interact with endogenously-expressed
SPAK and OSR1 in cell lysates under conditions in which the
dephosphorylated WNK4 peptide bound strongly to OSR1 [78]. This
result is particularly intriguing, because it suggests that the interac-
tion of RFXV motifs might be dynamically regulated by phosphory-
lation of nearby serine/threonine residues on WNK1 and WNK4.
Phosphorylation of this residue by another (as yet unknown) kinase
could trigger the dissociation ofWNK1 orWNK4 from SPAK and OSR1,
allowing SPAK/OSR1 to interact with their RFXV-motif-containing
targets including the cotransporters. Such an event could be triggered
by changes in intracellular chloride and/or cell volume. These data
establish that the CCT domain functions as a multipurpose docking
site, enabling SPAK/OSR1 to interact with its downstream substrates
(NKCC1) and upstream activators (WNK1/WNK4) [69].
In addition to physically interacting with SPAK/OSR1, the WNK
isoforms activate SPAK and OSR1 by phosphorylating equivalent
residues located within the T-loop of their catalytic domains (Thr233
in SPAK, Thr185 in OSR1) [68,69]. Alanine mutagenesis has shown
that phosphorylation of these residues is essential for SPAK/OSR1's
activation in response to hypertonicity and cell shrinkage, as well as
their ability to physically interact with and phosphorylate NKCC1
[68,69,74,75]. WNKs phosphorylate other residues in SPAK/OSR1
(e.g., Thr243 in SPAK), but alanine mutagenesis of these residues
does not affect SPAK/OSR1's activation in response to hypertonicity
or its ability to activate NKCC1 [67,75]. Once activated, SPAK/OSR1
phosphorylates Thr199, Thr201, and Thr206 in NKCC1; phosphor-
ylation at Thr206 is essential for NKCC1's activation by hypertonicity
[75,76]. Binding of SPAK/OSR1 to NKCC1 is also necessary for
cotransporter activity under both baseline and hyperosmotic
conditions [76].
The functional interaction of WNKs and SPAK/OSR1 on NKCC1
was ﬁrst demonstrated in oocytes, as has been since recapitulated in
mammalian cell systems.While the activity of NKCC1was not shown
to be signiﬁcantly affected by co-expression of SPAK in oocytes [21],
the ﬁnding that a dominant-negative SPAK mutant dramatically
reduced the regulatory phosphorylation and activity of NKCC1 in low
intracellular chloride (activating) conditions suggested that SPAK
might be a key element downstream of the chloride-sensing
mechanism that regulates NKCC1 [21]. This interaction was found
to be of important functional signiﬁcance, as co-expression of SPAK
andWNK4 together, but not alone, robustly increased NKCC1 activity
in a manner insensitive to conditions of external osmolarity [69,74].
This activation was dependent on the catalytic activities of SPAK and
WNK4, and SPAK's physical interaction with bothWNK4 and NKCC1.
OSR1 exhibited similar functional activation of NKCC1 when co-
expressed with WNK1 [69]. Genetically engineered SPAK knock-in
mice in which the T-loop threonine residue (Thr243) wasmutated to
alanine to prevent activation by WNK isoforms exhibit markedly
reduced phosphorylation of NCC and NKCC2 cotransporters at the
residues phosphorylated by SPAK, and display signiﬁcantly reduced
salt-dependent blood pressure, consistent with a loss of function of
NCC and NKCC2 [80].
Equally important to the activation of NKCC1 by hypertonicity and
cell shrinkage is its deactivation in response to hypotonicity and cell
swelling, which occurs secondary to cotransporter dephosphorylation
1154 K.T. Kahle et al. / Biochimica et Biophysica Acta 1802 (2010) 1150–1158by phosphatases. NKCC1 activity is stimulated by protein phospha-
tase 1 (PP1) inhibitors; however, it has been unclear how PP1 exerts
its inhibitory effect on NKCC1 during hypotonicity: does PP1 act
directly on the cotransporter, or indirectly by affecting an activating
kinase like WNK or SPAK? Recently, Delpire and colleagues shed
insight into the mechanism by which NKCC1 is inhibited by PP1, by
showing that mutation of key residues in the PP1 binding motif
located in the N-terminal tail of NKCC1 signiﬁcantly reduces the
inhibitory effect of PP1, and that PP1 dephosphorylates the
cotransporter and SPAK in a time-dependent manner [81]. Impor-
tantly, PP1's dephosphorylation of SPAK was signiﬁcantly greater
when SPAK and the N-terminal tail of NKCC1 were in a physical
complex with one another in the reaction, indicating the necessity of
scaffolding of PP1 and SPAK in proximity to one another. These data
are consistent with a model where PP1 inhibits NKCC1 activity
directly by dephosphorylating the cotransporter, and also indirectly
by dephosphorylating its proximal-most activating kinase, SPAK [81].
At present, it is unclear if PP1 dephosphorylates the WNK kinases.
This will be an important question for future experiments, since
WNK1/4 exists in a complex with SPAK in cells.5. WNK kinase regulation of K–Cl cotransport
Exploration of WNK/Ste20-type kinase regulation of the K–Cl
cotransporters has lagged behind that of the Na–K–2Cl cotranspor-
ters until recently. It seems that, in contrast to their effect on NKCC1,
SPAK/OSR1 seem to play minor roles in the WNK-dependent
regulation of the KCCs [82–84]. A breakthrough study by Rinehart
et al. [84], which utilized novel, titanium dioxide-based phospho-
peptide enrichment followed by two techniques that allowed for the
quantitative assessment of dynamic changes in KCC phosphorylation
under hypotonic (activating) and hypertonic (inactivating) condi-
tions (SILAC, or stable isotope labeling of amino acids in cell culture;
and MRM, or multiple reactive monitoring, which measures the
absolute percentage of phosphorylation at speciﬁc target sites)
identiﬁed two essential sites of phosphorylation (T991 and T1048) in
KCC3 that mediate its inactivation during hypertonic/cell shrinkage
in both cell culture and in mature human erythrocytes. WNK1, but
not SPAK or OSR1, is necessary for the phosphorylation of these
residues of KCC3 [84]. RNAi with multiple siRNAs against WNK1,
WNK2, WNK3, WNK4, SPAK, and OSR1 in HEK-KCC3tetON cells,
demonstrated that only WNK1 was necessary for the hypertonicity-
induced phosphorylation and inhibition of KCC3 at T991 and T1048.
Whether this effect is mediated by direct phosphorylation of KCC3 by
WNK1, or via the activation of other kinases that act at these sites is
unknown. Alternatively, WNK1 could negatively regulate phospha-
tase activity. These possibilities will require further experiments for
elucidation. These regulatory sites on KCC3 are also present in other
KCCs, including KCC2, and have been shown to be essential for KCC2's
full activation in mammalian cells. Alanine substitutions introduced
into KCC2 at positions Thr 906 and 1007 (the equivalent residues to
T991 and T1048 in KCC3) resulted in a 4-fold increase in KCC2 activity
compared with wild-type KCC2 in HEK293 cells under isotonic
conditions, as assayed by KCC-dependent 86Rb uptake [84]. More-
over, in the developing brain, the phosphorylation state of KCC2 at
Thr 906 and 1007 parallels KCC2 activity, with essentially complete
dephosphorylation in the adult, when KCC2 activity is highest. These
are particularly intriguing results, suggesting that KCC2 phosphor-
ylation at these sites may play a role in regulation of [Cl−]i in
GABAergic neurons, in addition to other knownmechanisms of KCC2
regulation in the CNS such as regulation of transcript and protein
expression [85]. Additional experiments are needed to assess the
physiologic role of KCC2 phosphorylation in the brain and peripheral
nervous system. Interestingly, the sequence context of T991 in the
KCCs is also conserved in the amino-terminus of NKCC1, suggestingthat the same kinase could coordinately regulate the NKCCs and KCCs
via opposing effects these two transport pathways.6. WNK3: a brain-enriched WNK family member with reciprocal
actions on the Na–K–2Cl and K–Cl cotransporters
WNK3deserves specialmention, given its distinct expression proﬁle
and its opposing actions on the Na–K–2Cl and K–Cl cotransporters.
WNK3exists in several alternatively-spliced isoforms, including a brain-
speciﬁc isoform that contains a unique exon [86]. Like WNK1 and
WNK4, WNK3 localizes to the intercellular junctions of chloride-
transporting epithelia throughout the body [11]; however, unlike
WNK1 and WNK4, which are highly expressed in the kidney, WNK3 is
mosthighly expressed in thebrain. In situ analysis has shown thatWNK3
transcripts are robustly expressed in the several different cortical layers,
the hippocampus, reticular formation, hypothalamic nuclei (including
the supraoptic and suprachiasmatic nuclei), and the cerebellum, and
undergoes a dynamic developmental shift in expression that parallels
KCC2 in thehippocampus and cerebellum [11]. Recently, NKCC1, several
of the K–Cl cotransporters, and WNK3 have been shown to be co-
expressed in vasoactive intestinal peptide, gastrin-releasing peptide,
and vasopressin-releasing neurons in the suprachiasmatic nucleus [87],
an interesting phenomenon because neurons within the SCN are
capable of eliciting either an excitatory or inhibitory response to
GABA, depending on the cell's level of [Cl−]i [60].
WNK3modulates the balance between cellular chloride inﬂux and
efﬂux via reciprocal actions on the NKCCs and KCCs, and is able to
override the normal effects of variation in extracellular osmolarity on
cotransporter activity [11]. Co-expression of wild-type WNK3 with
NKCC1 in oocytes increases NKCC1 activity not only in hypertonic
media (the normal condition for assaying NKCC1 activity), but also in
hypotonic media (a condition in which NKCC1 is normally silenced)
[11]. Conversely, wild-type WNK3 inhibited each of the KCCs, even in
hypotonic media (a condition in which KCCs are normally maximally
active) [11]. A catalytically-silentWNK3mutant produced the mirror-
image effects of wild-type WNK3 on the cotransporters, inhibiting
NKCC1 but activating the KCCs [11]. Interestingly, kinase-inactive
WNK3's stimulation of the KCCs in hypertonic conditions is abolished
by calyculin A and cyclosporine A, implicating protein phosphatases
PP1 and 2B in this effect [82]. Wild-type WNK3 increases the
phosphorylation of the same Thr residues of NKCC1 phosphorylated
by SPAK/OSR1, and kinase-inactive WNK3 prevented the phosphor-
ylation of these essential residues, even in hypertonic (activating)
conditions [11].
These data suggest thatWNK3 can regulate [Cl−]i by dynamically
regulating balance between NKCC1 and KCC activities, depending on
whether WNK3 is itself “activated.” Presumably, this is achieved in
response to changes in extracellular tonicity, cell volume, and
intracellular chloride, though formal evidence is at present lacking.
However, insight into the mechanism of how WNK3 regulates its
targets was recently achieved by Ponce-Coria et al., who focused on
the target NKCC2 [77]. This group found that intracellular chloride
depletion activates NKCC2 by promoting the phosphorylation of the
cotransporter at homologous residues that are phosphorylated in
NKCC1 by SPAK/OSR1. Ponce-Coria et al. demonstrated that the
activation of NKCC2 in response to intracellular chloride depletion
was dependent on an interaction between WNK3 and SPAK, where
WNK3 is positioned upstreamof SPAK and appears to be the chloride-
sensitive kinase [77]. Elimination of WNK3's only SPAK-binding
motif prevents its activation of NKCC2. A catalytically-inactiveWNK3
mutant also completely prevents NKCC2 activation by intracellular
chloride depletion [77]. These data revealed a novel chloride-sensing
mechanism that regulates NKCC2, and provided insight into the
mechanismbywhich changes in the level of intracellular chloride can
alter cotransporter activity [77] (Fig. 2).
Fig. 2. Proposed model for intracellular chloride concentration [Cl−]i, WNK3, and SPAK interaction in the control of Na–K–2Cl cotransporter activity. Variations in [Cl−]i are likely
associated with changes in the ratio of active versus inactive WNK3 kinase (W3R). Low [Cl−]i activates WNK3, which phosphorylates and activates SPAK, which then binds,
phosphorylates, and activates the Na–K–2Cl cotransporters. See text for details.
From Ponce-Coria 2008.
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pathway
The ability to defend cell volume amidst changes in intracellular
solute content or extracellular osmolality is a fundamental property
common to cells in all species, since failure to do so would lead to
osmotic lysis due to excessive cell swelling. Hence, it seems likely that
common mechanisms of cell volume regulation would exist in
different organisms through evolutionary conservation. Strange and
colleagues have recently shown that the interaction between the
WNK and Ste20-type kinases is an evolutionarily-conserved pathway
that functions to regulate transepithelial ion transport and maintain
systemic osmotic homeostasis in C. elegans [26,82].
The SPAKworm homolog GCK-3 had been shown previously to bind
and negatively regulate the C. elegans chloride channel CLH-3b, which is
activated in response to cell swelling by serine/threonine dephosphor-
ylationeventsmediated by the type 1phosphatasesGLC-7α andGLC-7β
[88]. CLH-3b is orthologous to the mammalian volume-sensitive and
voltage-gated ClC-2 chloride channel, which is mutated in idiopathic
generalized epilepsy, an inherited neurological disorder affecting about
0.4% of the world's population [89]. By constructing genetically-
engineered worms whose expression of GFP is driven by the
endogenous gene's promoter, Strange's group demonstrated that both
GCK-3 and the singleWNKortholog inworms,WNK-1, are expressed in
the excretory cell (the worm-equivalent of the mammalian kidney),
which plays a role in systemic osmoregulation [26].Worms genetically-
engineered with tissue-speciﬁc RNAi of GCK-3 had a dramatically
impaired systemic volume recovery and survival after hypertonic
shrinkage.WNK-1 was shown to bind to GCK-3 in the yeast two-hybrid
system, and knockdown of WNK-1 produced a phenotype similar to
GCK-3 (RNAi) worms [26]. Because knockdown of GCK-3 and WNK-1
together had no additive effect, these kinases were postulated to
function in a common pathway in amanner similar to theirmammalianhomologs,withWNK-1upstreamofGCK-3 [26]. Deletion of either of the
worm WNK-1 or GCK-3 genes resulted in the Exc phenotype, which
includes a defect in the tubular extension of excretory cells [90].
Expression of the activated form of GCK-3 or the CLH-3 deletion
mutation partly suppresses the phenotype of the WNK-1 or GCK-3
deletion mutants, suggesting that WNK-1, by activating GCK-3 and
triggering the down-regulation of CIC channel activity, controls the
tubular formation of excretory canals [90].
Phylogenetic analysis of the kinase domains of the Ste20-type and
WNK kinases by Choe et al. suggests that the interaction between these
two kinase families ﬁrst evolved in the early metazoan lineage [26].
Evolutionarily, this would have coincided with the emergence of
multicellular organisms that contain different ﬂuid compartments
separated by epithelial cell sheets, and the need to precisely regulate
the ionic andosmotic composition of thesedifferentﬂuids. The evidence
provided by Strange and colleagues suggest the compelling possibility
that the WNKs and the Ste20-type kinases arose early in animal
evolution as a mechanism to regulate the epithelial transport processes
of early metazoans, a function that is still crucial in humans today [91].
8. Closing comments
Since it was ﬁrst hypothesized that a single “chloride/volume-
sensitive kinase” regulates the Na–K–2Cl and K–Cl cotransporters, it
has become increasingly clear that this model is far too simple. The
current paradigm suggests that a more complex system, comprised
osmosensors like the WNK kinases, and associated downstream
transducer kinases like SPAK/OSR1, works in concert to orchestrate
this regulation. This system is important for maintaining cell volume
during osmotic stress, executing transepithelial solute and water
transport, and may be important for modulating the response
(excitation versus inhibition) to GABA (Fig. 3). Further complexity,
not fully developed in this review, is added by the fact that WNKs
Fig. 3. Model of WNK kinase phosphoregulation of the Na–K–2Cl and K–Cl
cotransporters. Low intracellular chloride concentration [Cl−]i and/or extracellular
hypertonicity (resulting in cell shrinkage) activates WNK kinase(s) via autopho-
sphorylation or activation by an unknown upstream kinase. Activated WNKs, in turn,
bind, phosphorylate, and activate SPAK/OSR1, which then binds to NKCC1 and activates
it by promoting its phosphorylation at key amino-terminal residues in its cytoplasmic
tail. Under similar conditions, WNKs trigger the net phosphorylation and inhibition of
the K–Cl cotransporters, either directly or indirectly via the inactivation of a
phosphatase.
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of one another's activity; for example, WNK1 phosphorylates both
WNK2 and WNK4 and is a negative regulator of WNK4-mediated
effects (e.g., 9), yet both kinases have been shown to activate SPAK/
OSR1 [75]. Moreover, for a given WNK, like WNK1, tissue-speciﬁc
isoforms exist (e.g., both WNK1 and WNK4 have kidney-speciﬁc
isoforms, and WNK1 and WNK3 have brain-speciﬁc isoforms)
[1,25,86]. Additionally, WNKs have been shown to regulate another
serine–threonine kinase, SGK-1 [3], which has a known role in cell
volume regulation [38]. Given this complexity, it seems like unbiased
genetic analyses, in combination with in vitro and in vivo physiological
characterization, will continue to be useful tools to dissect out the
details of this important, evolutionarily-conserved pathway and
identify the prime targets for therapeutic drug development. For
example, molecular genetic analysis has recently shown that
autosomal recessive disease hereditary sensory and autonomic
neuropathy type 2 (HSAN2), an early-onset disorder characterized
by loss of perception to pain, touch, and heat due to a loss of
peripheral sensory nerves, results from mutations in the nervous
system-speciﬁc exon of WNK1 [25]. This ﬁnding, especially in light of
the demonstrated ability of WNK1 to regulate both NKCC1 and the K–
Cl cotransporters like KCC2 and KCC3, suggests that investigation into
the neuronal-speciﬁc isoform of WNK1 might prove beneﬁcial for
targeting pain syndromes. Genetic investigation of the WNKs in
model systems like D. melanogaster and C. elegans, which have single
WNK homologs, may also be useful, given the tractability and
established proteomic networks of these organisms. An increased
understanding of how the WNKs regulate the Na–K–2Cl and K–Cl
cotransporters may provide novel opportunities for the selective
modulation of these transporters, with ramiﬁcations for common
human diseases like hypertension, sickle cell disease, neuropathic
pain, and epilepsy.References
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